120 related articles for article (PubMed ID: 36733008)
1. [Long-Term Survival following Multidisciplinary Therapy for Unresectable Pancreatic Body Cancer].
Mineta S; Okada T; Sanuki F; Iwamoto R; Kitagawa S; Kinoshita S; Ueno M; Kubota H; Tanaka H; Higashida M; Ito Y; Endo S; Yoshimatsu K; Fujiwara Y; Ueno T
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1814-1816. PubMed ID: 36733008
[TBL] [Abstract][Full Text] [Related]
2. GEM + nab-PTX Therapy for Pancreatic Body Cancer cStage IVb for Conversion Surgery: A Case Report.
Yoshii H; Izumi H; Abe R; Tajiri T; Mukai M; Nomura E; Makuuchi H
Tokai J Exp Clin Med; 2019 Dec; 44(4):85-89. PubMed ID: 31768996
[TBL] [Abstract][Full Text] [Related]
3. A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine.
Hiyoshi M; Nanashima A; Wada T; Tsuchimochi Y; Hamada T; Yano K; Imamura N; Fujii Y
Clin J Gastroenterol; 2017 Dec; 10(6):551-557. PubMed ID: 29086227
[TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
5. [Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report].
Nakamoto S; Nishiyama R; Kaneda T; Yokota M; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Yamauchi H; Okuwaki K; Iwai T; Imaizumi H; Suzuki E; Hara A; Ichinoe M; Kida M; Watanabe M
Gan To Kagaku Ryoho; 2017 Feb; 44(2):173-176. PubMed ID: 28223678
[TBL] [Abstract][Full Text] [Related]
6. [A Case of Conversion Surgery after Long-Term Chemotherapy for Pancreatic Cancer with Peritoneal Metastasis].
Enoki M; Gotoh K; Sakai K; Toshiyama R; Yanagisawa K; Kawai K; Miyo M; Takahashi Y; Hamakawa T; Doi T; Takeno A; Katoh T; Takami K; Hirao M
Gan To Kagaku Ryoho; 2023 Jan; 50(1):87-89. PubMed ID: 36759995
[TBL] [Abstract][Full Text] [Related]
7. [Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer].
Katsura Y; Takeda Y; Ohmura Y; Motoyama Y; Ishida T; Morimoto Y; Matsushita K; Naito A; Murakami K; Kagawa Y; Okishiro M; Takeno A; Egawa C; Kato T; Tamura S
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2367-9. PubMed ID: 26805366
[TBL] [Abstract][Full Text] [Related]
8. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
[TBL] [Abstract][Full Text] [Related]
9. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A
Ann Oncol; 2016 Apr; 27(4):654-60. PubMed ID: 26802160
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis.
Takahara N; Nakai Y; Ishigami H; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Yamashita H; Isayama H; Seto Y; Koike K
Invest New Drugs; 2021 Feb; 39(1):175-181. PubMed ID: 32772340
[TBL] [Abstract][Full Text] [Related]
11. [A Case of Boderline Resectable Pancreatic Cancer Curatively Resected after Chemotherapy with Gemcitabine and Nab-Paclitaxel].
Kuwayama N; Natsume T; Kainuma O; Maruyama T; Tanaka H; Miyazaki A; Sato Y; Note H; Yoshioka T; Matsumoto Y; Suzuki K; Kato M; Oshima S; Ishigaki A; Mizumoto H; Shimizu S
Gan To Kagaku Ryoho; 2019 Apr; 46(4):721-724. PubMed ID: 31164515
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
13. [Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience].
Takeda Y; Katsura Y; Ohmura Y; Sakamoto T; Akiyama Y; Kuwahara R; Morimoto Y; Ishida T; Oneda Y; Murakami K; Naito A; Kagawa Y; Takeno A; Kato T; Tamura S
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1674-1677. PubMed ID: 28133095
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer.
Kawaida H; Kono H; Amemiya H; Saitou R; Yamamoto A; Hosomura N; Watanabe M; Kimura A; Furuya S; Shimizu H; Akaike H; Kawaguchi Y; Sudo M; Itakura J; Hayakawa H; Shindo H; Takahashi EI; Takano S; Fukasawa M; Ichikawa S; Fujii H; Ichikawa D
Anticancer Res; 2018 Nov; 38(11):6537-6542. PubMed ID: 30396983
[TBL] [Abstract][Full Text] [Related]
15. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
[TBL] [Abstract][Full Text] [Related]
16. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
17. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
Gharaibeh M; McBride A; Bootman JL; Patel H; Abraham I
J Med Econ; 2017 Apr; 20(4):345-352. PubMed ID: 27919186
[TBL] [Abstract][Full Text] [Related]
19. A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer.
Hasegawa R; Okuwaki K; Kida M; Yamauchi H; Kawaguchi Y; Matsumoto T; Kaneko T; Miyata E; Uehara K; Iwai T; Watanabe M; Kurosu T; Imaizumi H; Ohno T; Koizumi W
Int J Clin Oncol; 2019 Dec; 24(12):1574-1581. PubMed ID: 31309381
[TBL] [Abstract][Full Text] [Related]
20. [A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemodialysis].
Okazaki M; Tajima H; Ohbatake Y; Terai S; Nakanuma S; Okamoto K; Sakai S; Makino I; Kinoshita J; Nakamura K; Miyashita T; Takamura H; Ninomiya I; Fushida S; Ohta T
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2162-2164. PubMed ID: 30692318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
